Therapeutic options in post-transplant lymphoproliferative disorders

Therapeutic Advances in Hematology

Volumn 2, Issue 6, 2011, Pages 393-407

  Zimmermann, Heiner ^a   Trappe, Ralf Ulrich ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

antiviral therapy; CHOP; cytotoxic T cells; immunosuppression reduction; interferon alpha; post transplant lymphoproliferative disorders (PTLD); rituximab; treatment

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LATENT MEMBRANE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRAFT REJECTION; ACUTE HEART INFARCTION; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CELL THERAPY; CREATININE BLOOD LEVEL; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FATIGUE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; VIRUS LOAD; WEAKNESS;

EID: 84993734344     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711412417     Document Type: Review

References (86)

1. Allen U. Hebert D. Moore D. Dror Y. Wasfy S. (2001) Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: a Canadian multi-centre experience. Pediatr Transplant 5: 198–203.
2. Babcock G.J. Decker L.L. Freeman R.B. Thorley-Lawson D.A. (1999) Epstein–Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190: 567–576.
3. Birkeland S.A. Hamilton-Dutoit S. (2003) Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?. Transplantation 76: 984–988.
4. Blaes A.H. Peterson B.A. Bartlett N. Dunn D.L. Morrison V.A. (2005) Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 104: 1661–1667.
5. Cantarovich M. Barkun J.S. Forbes R.D. Kosiuk J.P. Tchervenkov J.I. (1998) Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant 12: 109–115.
6. Cartron G. Trappe R.U. Solal-Celigny P. Hallek M. (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 17: 19–30.
7. Cavaliere R. Petroni G. Lopes M.B. Schiff D. (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 116: 863–870.
8. Choquet S. Leblond V. Herbrecht R. Socie G. Stoppa A.M. Vandenberghe P. et al. (2006) Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 107: 3053–3057.
9. Choquet S. Oertel S. Anagnostopoulos I. Riess H. Uzunov M. Leblond V.e. et al. (2008) Results of the largest study on post-transplant-lymphoproliferations (PTLDs) of the central nervous system (CNS) in the rituximab era: a surprising overrepresentation of kidney transplantations, key importance of methotrexate (Mtx), cytarabine (AraC) and radiotherapy (RX) for long term survival and low impact of rituximab (R). ASH Annual Meeting Abstracts 112: 3614.
10. Choquet S. Oertel S. Le Blond V. Riess H. Varoqueaux N. Dorken B. et al. (2007 a) Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 86: 599–607.
11. Choquet S. Trappe R. Leblond V. Jager U. Davi F. Oertel S. (2007 b) CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92: 273–274.
12. Davis C.L. Wood B.L. Sabath D.E. Joseph J.S. Stehman-Breen C. Broudy V.C. (1998) Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66: 1770–1779.
13. Dayde D. Ternant D. Ohresser M. Lerondel S. Pesnel S. Watier H. et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic–pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113: 8.
14. Dharnidharka V.R. Sullivan E.K. Stablein D.M. Tejani A.H. Harmon W.E. (2001) Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71: 1065–1068.
15. Duvoux C. Pageaux G.P. Vanlemmens C. Roudot-Thoraval F. Vincens-Rolland A.L. Hezode C. et al. (2002) Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74: 1103–1109.
16. Elstrom R.L. Andreadis C. Aqui N.A. Ahya V.N. Bloom R.D. Brozena S.C. et al. (2006) Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6: 569–576.
17. Evens A.M. David K.A. Helenowski I. Nelson B. Kaufman D. Kircher S.M. et al. (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28: 1038–1046.
18. Fellner M.D. Durand K. Correa M. Bes D. Alonio L.V. Teyssie A.R. et al. (2003) A semiquantitative PCR method (SQ-PCR) to measure Epstein–Barr virus (EBV) load: its application in transplant patients. J Clin Virol 28: 323–330.
19. Fleisher G. Henle W. Henle G. Lennette E.T. Biggar R.J. (1979) Primary infection with Epstein–Barr virus in infants in the United States: clinical and serologic observations. J Infect Dis 139: 553–558.
20. Fohrer C. Caillard S. Koumarianou A. Ellero B. Woehl-Jaegle M.L. Meyer C. et al. (2006) Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 134: 602–612.
21. Gao S.Z. Chaparro S.V. Perlroth M. Montoya J.G. Miller J.L. Di Miceli S. et al. (2003) Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 22: 505–514.
22. Garrett T.J. Chadburn A. Barr M.L. Drusin R.E. Chen J.M. Schulman L.L. et al. (1993) Posttransplantation lymphoproliferative disorders treated with cyclophosphamide–doxorubicin–vincristine–prednisone chemotherapy. Cancer 72: 2782–2785.
23. Gisselbrecht C. Glass B. Mounier N. Singh Gill D. Linch D.C. Trneny M. et al. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28: 4184–4190.
24. Glez-Chamorro A. Jimenez C. Moreno-Glez E. Glez-Pinto I. Loinaz C. Gomez R. et al. (2000) Management and outcome of liver recipients with post-transplant lymphoproliferative disease. Hepatogastroenterology 47: 211–219.
25. Gonzalez-Barca E. Domingo-Domenech E. Capote F.J. Gomez-Codina J. Salar A. Bailen A. et al. (2007) Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 92: 1489–1494.
26. Green M. Cacciarelli T.V. Mazariegos G.V. Sigurdsson L. Qu L. Rowe D.T. et al. (1998) Serial measurement of Epstein–Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 66: 1641–1644.
27. Haddad E. Paczesny S. Leblond V. Seigneurin J.M. Stern M. Achkar A. et al. (2001) Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97: 1590–1597.
28. Haque T. Wilkie G.M. Jones M.M. Higgins C.D. Urquhart G. Wingate P. et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123–1131.
29. Heslop H.E. Ng C.Y. Li C. Smith C.A. Loftin S.K. Krance R.A. et al. (1996) Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2: 551–555.
30. Jain A. Nalesnik M. Reyes J. Pokharna R. Mazariegos G. Green M. et al. (2002) Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 236: 429–436; discussion 436-427.
31. Katz B.Z. Pahl E. Crawford S.E. Kostyk M.C. Rodgers S. Seshadri R. et al. (2007) Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant 11: 58–65.
32. Kenagy D.N. Schlesinger Y. Weck K. Ritter J.H. Gaudreault-Keener M.M. Storch G.A. (1995) Epstein–Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60: 547–554.
33. Kogan D.L. Burroughs M. Emre S. Fishbein T. Moscona A. Ramson C. et al. (1999) Prospective longitudinal analysis of quantitative Epstein–Barr virus polymerase chain reaction in pediatric liver transplant recipients. Transplantation 67: 1068–1070.
34. Kremers W.K. Devarbhavi H.C. Wiesner R.H. Krom R.A. Macon W.R. Habermann T.M. (2006) Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6: 1017–1024.
35. Lemoine A. Pham P. Azoulay D. Saliba F. Emile J.F. Saffroy R. et al. (2001) Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood 98: 1332–1338.
36. Libertiny G. Watson C.J. Gray D.W. Welsh K.I. Morris P.J. (2001) Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 88: 1330–1334.
37. Liebowitz D. (1998) Epstein–Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338: 1413–1421.
38. Mamzer-Bruneel M.F. Lome C. Morelon E. Levy V. Bourquelot P. Jacobs F. et al. (2000) Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 18: 3622–3632.
39. Ng C.M. Bruno R. Combs D. Davies B. (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45: 792–801.
40. Norin S. Kimby E. Ericzon B.G. Christensson B. Sander B. Soderdahl G. et al. (2004) Posttransplant lymphoma–a single-center experience of 500 liver transplantations. Med Oncol 21: 273–284.
41. O'Brien S. Bernert R.A. Logan J.L. Lien Y.H. (1997) Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 8: 1483–1489.
42. Oertel S.H. Anagnostopoulos I. Hummel M.W. Jonas S. Riess H.B. (2002) Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 118: 1120–1123.
43. Oertel S.H. Papp-Vary M. Anagnostopoulos I. Hummel M.W. Jonas S. Riess H.B. (2003) Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 123: 830–835.
44. Oertel S.H. Verschuuren E. Reinke P. Zeidler K. Papp-Vary M. Babel N. et al. (2005) Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5: 2901–2906.
45. Orentas R.J. Schauer D.W. Jr. Ellis F.W. Walczak J. Casper J.T. Margolis D.A. (2003) Monitoring and modulation of Epstein–Barr virus loads in pediatric transplant patients. Pediatr Transplant 7: 305–314.
46. Pageaux G.P. Bonnardet A. Picot M.C. Perrigault P.F. Coste V. Navarro F. et al. (1998) Prevalence of monoclonal immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation 65: 397–400.
47. Papadopoulos N.G. Dedoussis G.V. Spanakos G. Gritzapis A.D. Baxevanis C.N. Papamichail M. (1994) An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 177: 101–111.
48. Paranjothi S. Yusen R.D. Kraus M.D. Lynch J.P. Patterson G.A. Trulock E.P. (2001) Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 20: 1054–1063.
49. Penn I. Hammond W. Brettschneider L. Starzl T.E. (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1: 106–112.
50. Perrine S.P. Hermine O. Small T. Suarez F. O'Reilly R. Boulad F. et al. (2007) A phase 1 / 2 trial of arginine butyrate and ganciclovir in patients with Epstein–Barr virus-associated lymphoid malignancies. Blood 109: 2571–2578.
51. Pfreundschuh M. Ho A.D. Cavallin-Stahl E. Wolf M. Pettengell R. Vasova I. et al. (2008 a) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9: 435–444.
52. Pfreundschuh M. Zeynalova S. Poeschel V. Haenel M. Schmitz N. Ho A.D. et al. (2008 b) Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol (Meeting Abstracts) 26(15 Suppl.): 8508.
53. Ramalingam P. Rybicki L. Smith M.D. Abrahams N.A. Tubbs R.R. Pettay J. et al. (2002) Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 15: 647–656.
54. Reams B.D. McAdams H.P. Howell D.N. Steele M.P. Davis R.D. Palmer S.M. (2003) Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 124: 1242–1249.
55. Reshef R. Vardhanabhuti S. Luskin M.R. Heitjan D.F. Hadjiliadis D. Goral S. et al. (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(bigstar). Am J Transplant 11: 336–347.
56. Riddler S.A. Breinig M.C. McKnight J.L. (1994) Increased levels of circulating Epstein–Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84: 972–984.
57. Rooney C.M. Smith C.A. Ng C.Y. Loftin S. Li C. Krance R.A. et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 345: 9–13.
58. Rowe D.T. Qu L. Reyes J. Jabbour N. Yunis E. Putnam P. et al. (1997) Use of quantitative competitive PCR to measure Epstein–Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35: 1612–1615.
59. Rowe D.T. Webber S. Schauer E.M. Reyes J. Green M. (2001) Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 3: 79–87.
60. Schaar C.G. van der Pijl J.W. van Hoek B. de Fijter J.W. Veenendaal R.A. Kluin P.M. et al. (2001) Successful outcome with a “quintuple approach” of posttransplant lymphoproliferative disorder. Transplantation 71: 47–52.
61. Scheenstra R. Verschuuren E.A. de Haan A. Slooff M.J. The T.H. Bijleveld C.M. et al. (2004) The value of prospective monitoring of Epstein–Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis 6: 15–22.
62. Shahinian V.B. Muirhead N. Jevnikar A.M. Leckie S.H. Khakhar A.K. Luke P.P. et al. (2003) Epstein–Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 75: 851–856.
63. Smith J.M. Corey L. Healey P.J. Davis C.L. McDonald R.A. (2007) Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein–Barr virus infection than younger renal transplant recipients. Transplantation 83: 1423–1428.
64. Starzl T.E. Nalesnik M.A. Porter K.A. Ho M. Iwatsuki S. Griffith B.P. et al. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1: 583–587.
65. Swerdlow S.H. Webber S.A. Chadburn A. Ferry J.A. (2008) Post-transplant lymphoproliferative disorders. In: Ed. Swerdlow S.H. Campo E. Harris N.L. Jaffe E.S. Pileri S.A. Stein H. (eds). WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues, 4th edn, World Health Organization: Geneva, pp. 343–350.
66. Swinnen L.J. (2000) Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 11(Suppl. 1): 45–48.
67. Swinnen L.J. Le Blanc M. Grogan T.M. Gordon L.I. Stiff P.J. Miller A.M. et al. (2008) Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 86: 215–222.
68. Taguchi Y. Purtilo D.T. Okano M. (1994) The effect of intravenous immunoglobulin and interferon-alpha on Epstein–Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 57: 1813–1815.
69. Taylor A.L. Bowles K.M. Callaghan C.J. Wimperis J.Z. Grant J.W. Marcus R.E. et al. (2006) Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 82: 375–381.
70. Trappe R. Choquet S. Oertel S. Leblond V. Ekman T. Sender M. et al. (2007 a) Sequential treatment with rituximab and CHOP chemotherapy in B-Cell PTLD - a new standard in therapy?. Blood 110: 390.
71. Trappe R. Choquet S. Oertel S.H.K. Leblond V. Dierickx D. Mollee P. et al. (2009 a) Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD - moving forward to a first standard of care: results from a prospective international multicenter trial. ASH Annual Meeting Abstracts 114: 100.
72. Trappe R. Hinrichs C. Appel U. Babel N. Reinke P. Neumayer H.H. et al. (2009 b) Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 9: 2331–2337.
73. Trappe R. Riess H. Anagnostopoulos I. Neuhaus R. Gartner B.C. Pohl H. et al. (2009 c) Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone. Ann Hematol 88: 167–172.
74. Trappe R. Riess H. Babel N. Hummel M. Lehmkuhl H. Jonas S. et al. (2007 b) Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 83: 912–918.
75. Trappe R. Zimmermann H. Fink S. Reinke P. Dreyling M. Pascher A. et al. (2011) Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease - a prospective analysis of 8 cases. Haematologica, in press.
76. Trappe R.U. Choquet S. Reinke P. Dreyling M. Mergenthaler H.G. Jager U. et al. (2007 c) Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. Transplantation 84: 1708–1712.
77. Tsai D.E. Hardy C.L. Tomaszewski J.E. Kotloff R.M. Oltoff K.M. Somer B.G. et al. (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71: 1076–1088.
78. Vajro P. Lucariello S. Migliaro F. Sokal E. Gridelli B. Vegnente A. et al. (2000) Predictive value of Epstein–Barr virus genome copy number and BZLF 1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. J Infect Dis 181: 2050–2054.
79. Vallejo G.H. Romero C.J. de Vicente J.C. (2005) Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol, in press.
80. Wagner H.J. Fischer L. Jabs W.J. Holbe M. Pethig K. Bucsky P. (2002) Longitudinal analysis of Epstein–Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 74: 656–664.
81. Webber S.A. Naftel D.C. Fricker F.J. Olesnevich P. Blume E.D. Addonizio L. et al. (2006) Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 367: 233–239.
82. Wu L. Rappaport D.C. Hanbidge A. Merchant N. Shepherd F.A. Greig P.D. (2001) Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging 26: 200–206.
83. Yancoski J. Danielian S. Ibanez J. Turconi A. Cuarterolo M. Zelazko M. et al. (2004) Quantification of Epstein–Barr virus load in Argentinean transplant recipients using real-time PCR. J Clin Virol 31: 58–65.
84. Yang J. Tao Q. Flinn I.W. Murray P.G. Post L.E. Ma H. et al. (2000) Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96: 4055–4063.
85. Young L. Alfieri C. Hennessy K. Evans H. O'Hara C. Anderson K.C. et al. (1989) Expression of Epstein–Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321: 1080–1085.
86. Zein N.N. Perez R.G. Wiesner R.H. (2000) Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation. Hepatology 31: 808–809.